Annika has been at Brann since 2013. She has a unique experience of strategic IP planning with commercial focus after her years as Global Head of IP at the Life Science Division of GE healthcare (today Cytiva). Today she is in charge of our office in Uppsala and except her stellar reputation within the field of IP matters, she is a very well-liked leader.
Annika is specialized in Life Science and has a vast background of IP protection of innovation within protein chemistry and instruments for biotechnical applications. Protein A ligands, and devising the successful patent strategy for MabSelect® to mention one. She is also experienced in offensive, as well as defensive, use of IP-protection using multiple rights to strengthen the exclusivity around a product. An example of this are the trials to protect the exclusive rights to Biacore® in USA and Europe. The trials regarded infringement in patent- and design rights and misleading marketing.
Annika is very engaged and involved in her work, and with a genuine interest in product development she has she has also been involved in remuneration of inventors including the setting up of processes from idea generation to patent filing and remuneration. Here, she has experience in disputes related the level of reasonable compensation in court as well as in arbitration.
Annika balances the work at Brann by spending her free time outdoors, preferably combined with speed, such as horseback riding.